Pharmaceutical composition comprising maple leaf extract for preventing or treating retinal disease
US-11564962-B2 · Jan 31, 2023 · US
Composition for treating corneal diseases or conjunctival diseases
US10357528B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10357528-B2 |
| Application number | US-201615742391-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jul 8, 2016 |
| Priority date | Jul 8, 2015 |
| Publication date | Jul 23, 2019 |
| Grant date | Jul 23, 2019 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention relates to a pharmaceutical composition for preventing and treating corneal diseases or conjunctival diseases, containing a maple leaf extract as an active ingredient. The maple leaf extract exhibits an effect of inhibiting hyperemia in the eyeball in which hyperemia has been induced and an effect of inhibiting angiogenesis in the eyeball in which corneal damage has been induced, thus being effectively used in a pharmaceutical composition for preventing and treating corneal diseases or conjunctival diseases.
First claim
Opening claim text (preview).
The invention claimed is: 1. A method for treating corneal diseases or conjunctival diseases, comprising a step of administering a pharmaceutically effective amount of a composition which comprises a maple leaf extract to the eyeball of a subject. 2. The method of claim 1 , wherein the maple leaf extract is an ethanol extract of maple leaves. 3. The method of claim 1 , wherein the maple leaf extract is a hot-water extract of maple leaves. 4. The method of claim 1 , wherein the corneal disease is any one selected from the group consisting of hyperemia, corneal angiogenesis, dry eye syndrome and keratitis. 5. The method of claim 1 , wherein the conjunctival disease is any one selected from the group consisting of conjunctivitis, pingueculitis, and pterygium. 6. The method of claim 1 , wherein the composition is an external preparation for the eyeball. 7. The method of claim 1 , wherein the composition further comprises a pharmaceutically acceptable carrier.
Assignees
Inventors
Classifications
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US10357528B2 cover?
- The present invention relates to a pharmaceutical composition for preventing and treating corneal diseases or conjunctival diseases, containing a maple leaf extract as an active ingredient. The maple leaf extract exhibits an effect of inhibiting hyperemia in the eyeball in which hyperemia has been induced and an effect of inhibiting angiogenesis in the eyeball in which corneal damage has been i…
- Who is the assignee on this patent?
- Korea Inst Oriental Medicine
- What technology area does this patent fall under?
- Primary CPC classification A61K36/20. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Jul 23 2019 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 5 related publications on this page (citations in our corpus or others sharing the same primary CPC).